This article is more than 5 years old. Information may no longer be current.

OnabotulinumtoxinA effective in treating crow's feet lines, glabellar lines

OnabotulinumtoxinA was effective and well-tolerated as a repeated treatment in patents with moderate-to-severe crow’s feet lines alone or combined with glabellar lines, according to recently published study results.

Jean Carruthers, MD, and colleagues conducted a multicenter, double-blind, 7-month study of 917 patients with moderate-to-severe crow’s feet lines (CFL) and glabellar lines (GL). The patients were assigned to receive treatment with onabotulinumtoxinA 44 U (CFL: 24 U, GL: 20 U), onobutlinumtoxinA 24 U (CFL: 24U, GL: placebo) or placebo. Treatment consisted of 11 injections, three in each CFL area and five in the GL area.

Jean Carruthers

The study’s primary endpoint was based on investigator and patient assessments of CFL severity at maximum smile using the Facial Wrinkle Scale (FWS). The proportion of patients who achieved at least a one-grade improvement in the CFL-FWS during maximum smile and at rest were secondary endpoints.

Primary and secondary endpoints were met, with onaboutlinumtoxinA being favored in statistically significant differences, according to the researchers. For CFL, investigator and subject responder rates were 54.9% and 45.8%, respectively; for CFL plus GL, investigator and subject responder rates were 59.0% and 48.5%, respectively; and for placebo, investigator and subject responder rates were each 3.3%.

OnabotulinumtoxinA treatments also were significantly favored in responder rates on the other endpoints, according to the researchers.

Mild-to-moderate adverse events (AEs) were reported in 9.6% of all patients, with two patients discontinuing treatment attributed to AEs — one because of myocardial infarction unrelated to treatment and one because of injection site pain.

“Improvements in appearance were generally numerically greater when CFL and GL areas were treated simultaneously,” the researchers concluded.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.